Rui Ma

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang, Zhehai Wang, Jian Fang et al. · Journal of Thoracic Oncology · 2020 · 396 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Shun Lü, Xiaorong Dong, Hong Jian et al. · Journal of Clinical Oncology · 2022 · 279 citations · Full text

Medicine, Oncology, Pharmacology +16

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Shun Lü, Jian Fang, Xingya Li et al. · The Lancet Respiratory Medicine · 2021 · 204 citations

Medicine, Oncology, Pharmacology +11

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

Yunpeng Yang, Jiya Sun, Zhehai Wang et al. · Journal of Thoracic Oncology · 2021 · 148 citations · Full text

Medicine, Oncology, Pharmacology +17

Tepotinib Treatment in Patients With <i>MET</i> Exon 14–Skipping Non–Small Cell Lung Cancer

Julien Mazières, Paul K. Paik, Marina Chiara Garassino et al. · JAMA Oncology · 2023 · 94 citations · Full text

Medicine, Oncology, Pharmacology +13